secwatch.observer — SEC 8-K summary
======================================

Issuer:     BriaCell Therapeutics Corp. (BCTX)
CIK:        0001610820
Form:       8-K
Filed at:   2023-05-15T23:59:59+00:00
Accession:  0001493152-23-017363
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BriaCell signs $4M stock purchase and CRO agreement with Prevail for pivotal breast cancer study
--------------------------------------------------------------------------------

- Prevail InfoWorks to serve as CRO for BriaCell's pivotal advanced metastatic breast cancer study, expected in 2023.
- BriaCell receives $4M from Prevail Partners for 463,408 shares at $8.63, a 20% premium to 30-day VWAP.
- Upfront payment of $5,379,945 under MST Agreement, plus milestone fees; funds used to pay InfoWorks.
- Stock purchase expected to close on or about May 19, 2023, subject to TSX approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1610820/000149315223017363/0001493152-23-017363-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1610820/000149315223017363/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-017363

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer